bioRxivCancer BiologyPreprint
The lipid kinase PI3Kα is required for the cohesion and survival of cancer cells disseminated in serous cavities.
Abstract
AO_SCPLOWBSTRACTC_SCPLOWBreast, ovarian, digestive and lung adenocarcinomas are often associated with the accumulation of malignant cells in serous cavities. As PI3K is one of the most mutated pathways in cancer, we investigated the importance of oncogenic PI3K in this process. We analyzed tumor cell organization in ascites from carcinomas at diagnosis. In some malignant ascites, tumor cells grew as adhesive coherent masses. Ex-vivo patient-derived cell cultures with the addition of mesenchymal stem cells, as a model of tumoral stroma, favored the compaction of tumorospheres. Ascites-derived ovarian cancer cell lines frequently harbored PIK3CA mutations coexisting with other mutations. PI3K promoted the formation and maintenance of multicellular adhesive PIK3CA-mutant spheroids, promoting cell survival. Cultures in 3D conditions as opposed to cultures in cell monolayers increased chemotherapy resistance, which was overcome by PI3K inhibition. We identified a signaling pathway of interest for the treatment of cancer cells disseminated in serous cavities, limiting cancer progression. Graphical abstractSchematic representation of PI3K involvement in tumor cell aggregates from ascites. 1) Known involvement of PI3K in primary ovarian tumors. 2) PI3K participates in tumorosphere formation within the peritoneum (treatment with PI3K inhibitors causes a delay in the formation of clusters). 3) PI3K participates in the maintenance of tumorospheres and in resistance to conventional treatment for peritoneal carcinomatosis. PI3K is a target to prevent transcoelomic dissemination and maintenance of tumorospheres in patients with ovarian cancer. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=87 SRC="FIGDIR/small/777649v3_ufig1.gif" ALT="Figure 1"> View larger version (24K): org.highwire.dtl.DTLVardef@15d4fa2org.highwire.dtl.DTLVardef@1175601org.highwire.dtl.DTLVardef@10f801dorg.highwire.dtl.DTLVardef@a41771_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: bulk RNA-seq
- assay: proteomics
- research focus: cancer & tumor microenvironment
- research focus: drug response / drug discovery
- research focus: cell type annotation
- approach: experimental assay
- approach: wet-lab / biochemical assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting the dependence on PIK3C3-mTORC1 signaling in dormancy-prone breast cancer cells blunts metastasis initiation
I. E. Elkholi, A. Robert, … J.-F. Cote·bioRxiv·Aug 2, 2023
- Ascites-Driven Modulation of Cell Phenotypes and Proteomes: Implications for Cancer Progression
Jack Scanlan, Parul Mittal, … Manuela Klingler‐Hoffmann·Clinical ProteomicsPeer-reviewed·Jun 28, 2026
- Loss of PIK3CA allows in vitro growth but not in vivo progression of KRAS mutant lung adenocarcinoma in a syngeneic orthotopic implantation model
Abigail Booth, Giuseppe Caso, … Harold Bien·CellsPeer-reviewed·Mar 12, 2026
- Pericyte-tumor crosstalk facilitates metastatic tumor cell latency through PIEZO1-activated lysophospholipid transfer.
Tamara McErlain, Morgan J. Glass, … Meera Murgai·bioRxiv·Feb 15, 2025
- AMPK-independent LKB1 activity is required for efficient epithelial ovarian cancer metastasis
A. Buensuceso, Y. Ramos Valdes, … T. Shepherd·bioRxiv·Mar 27, 2019
- Ascitic fluid protects against ferroptosis and enables the peritoneal spread of ovarian cancer
Yasaman Setayeshpour, S Chen, … Jen‐Tsan Chi·Nature CommunicationsPeer-reviewed·May 11, 2026